Skip to content

Advertisement

Open Access

PB.28. Determination of recall rates for assessment in women undergoing annual surveillance breast MRI: is a rate <10% achievable?

  • N Healy1,
  • S Cosgrove1,
  • P Wen1,
  • T Kwa1,
  • F O'Driscoll1,
  • G Offiah1,
  • Y Roden1,
  • S Sebaoui1,
  • K Wolohan1 and
  • S O'Keeffe1
Breast Cancer Research201416(Suppl 1):P28

https://doi.org/10.1186/bcr3720

Published: 3 November 2014

Keywords

Breast CancerStandard ProtocolGenetic MutationDevelop Breast CancerRecall Rate

Introduction

High recall rates from surveillance breast MRI are associated with patient anxiety and increased workload. NHSBSP guidelines recommend a maximum of a 10% recall rate with an expected rate of <7% in high-risk women undergoing surveillance with breast MRI. Our aims were to review surveillance breast MRIs performed at our institution from 2009 to 2013 to determine the recall rate and cancer detection rates.

Methods

Surveillance MRIs performed in women at high risk of developing breast cancer over a 5-year period were reviewed. Breast MRI was performed using a standard protocol on a 1.5 Tesla MRI. For all patients with a BIRADS MRI 0, 3, 4 or 5 score, additional imaging, modality of biopsy and histology were recorded.

Results

A total of 1,119 surveillance breast MRIs were performed over the 5-year period. These included women with a known genetic mutation or those at high risk based on genetic assessment. In total, 121 (10.8%) had BIRADS MRI scores which required recall for further imaging. Seventy-one patients (58.6%) had a biopsy performed and 19 cancers were detected, giving an overall cancer detection rate of 1.7%. Eleven (9%) were invasive ductal tumours. Of those recalled, 74 (61%) were in the prevalent round of screening.

Conclusion

While our data compare favourably with published data, the breast MRI recall rate is greater than the expected 7% recommended in the UK. This may be due to large numbers in the prevalent round.

Authors’ Affiliations

(1)
St James Hospital, Dublin, Ireland

Copyright

© Healy et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement